Press Release Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights Aug 4
Press Release Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Jul 23
Press Release Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors Jul 23